The place for eribulin in the treatment of metastatic breast cancer

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Treatment of metastatic breast cancer (MBC) remains one of the major challenges in cancer care. Chemotherapeutic agents currently approved for the treatment of invasive disease may exhibit initial efficacy; however, the development of resistance to therapy and concerns over tolerability are common and generally limit treatment options available to physicians and patients. Novel chemotherapeutic agents are, therefore, necessary to increase survival, delay disease progression, and improve tolerability. Eribulin mesylate (E7389) is a novel microtubule dynamics inhibitor with a unique mechanism of action that has shown antitumor efficacy and a manageable tolerability profile in clinical trials. Importantly, eribulin is the only single agent to date that has been shown to prolong overall survival in patients with heavily pretreated MBC. This review will discuss eribulin, with focus on the potential it has to address the specific treatment needs of patients with MBC who are refractory to conventional chemotherapies.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalCurrent oncology reports
Issue number1
StatePublished - Feb 2011


  • Chemotherapy
  • Eribulin mesylate
  • Metastatic breast cancer
  • Microtubule dynamics inhibitor

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'The place for eribulin in the treatment of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this